Abzena, the top-tier end-to-end integrated CDMO for intricate biologics and bioconjugates, has exciting news for the biopharma world. They’ve amped up their AbZelectPRO cell line development platform with the debut of two revolutionary Glutamine Synthetase (GS) knockout CHO-K1 expression systems. These include a double knockout ADCC+ platform tailored for afucosylated proteins, marking a leap in biopharma innovation. By rolling out these new GS knockout cell lines, Abzena is taking speed, scalability, and flexibility to soaring new heights for their esteemed biopharma clientele.
Elevating Biopharma Success with AbZelectPRO-KO and AbZelectPRO-KO+
- The AbZelectPRO-KO and AbZelectPRO-KO+ platforms are game-changers, offering unparalleled advantages for biopharma researchers.
- These cutting-edge GS knockout systems are available as standalone CLD options or as part of a comprehensive GMP program, boasting transparent pricing all the way to IND submission without any pesky royalty fees.
- Flexibility is key here, empowering customers to pick a CLD approach that perfectly syncs with their project-specific objectives, timelines, and financial plans.
Campbell Bunce, the Chief Scientific Officer at Abzena, beams with pride as he shares, “We’re all about fortifying our partnerships with customers by delivering out-of-the-box solutions and cutting-edge technologies that cater to their needs throughout the drug development journey. The integration of these new GS knockout cell lines into our AbZelectPRO CLD platform is a potent fusion that truly sets a fresh benchmark of excellence. We’re thrilled to offer such a robust, scalable, and state-of-the-art solution to bolster our customers’ therapeutic antibodies and challenging-to-express proteins.”
Powering Innovation with Revvity and ProteoNic Collaboration
- Licensed from Revvity, the GS knockout CHOSOURCE expression systems have been seamlessly woven into Abzena’s AbZelectPRO CLD workflow.
- These platforms are complemented by ProteoNic Bioscience’s cutting-edge 2G UNic vector technology, a match made in biopharma heaven.
- This cohesive approach has been proven to ramp up productivity and adaptability significantly, enabling biopharma clients to swiftly transition from DNA to research cell banks (RCB) in a mere 10 weeks, all while achieving high-performing titers of up to 10g/L.
Frank Pieper, the CEO of ProteoNic, proudly asserts, “Our 2G UNic vector technology continues to raise the bar within Abzena’s AbZelectPRO platform. By enhancing productivity in CHOSOURCE and other cell lines, ProteoNic’s technology cements the value of this offering for biopharma customers, setting a new gold standard in the industry.”
Bryan Kipp, the Senior Vice President of Technology & Licensing at Revvity, exclaims, “At Revvity, we don’t just meet expectations; we surpass them. The expanded cell line development platform at Abzena, which now includes our esteemed CHOSOURCE cell lines, directly addresses the pressing challenges faced by customers, boosting productivity and flexibility. Ultimately, Abzena’s approach will drive significant impact for customers, a mission we wholeheartedly endorse and champion.”
Revolutionizing Biopharma with Industry-Leading Cell Lines
- Revvity’s proprietary CHOSOURCE GS knockout cell line is a pinnacle of industry standards, a cGMP-manufactured CHO-K1-derived suspension cell line that has left its mark in over 90 IND filings and features in four approved drugs on the market.
- The CHOSOURCE ADCC+ cell line, a brainchild of Revvity, is a dual knockout of the glutamine synthetase (GS) & fucosyltransferase genes, elevating the game for biopharma researchers.
Abzena stands tall as the premier end-to-end bioconjugate and complex biologics CDMO + CRO, providing unwavering support to customers from discovery through commercial launch. Their fully integrated programs and a la carte services are meticulously crafted to mitigate risks and streamline the development journey of new treatments for patients in dire need.
ProteoNic, a trailblazing biotech company nestled in Leiden, The Netherlands, shines in the realm of advanced cell line generation and viral vector production. With a sharp focus on enhancing protein production efficiency and yield through their proprietary 2G UNic vector technology, ProteoNic is at the forefront of biopharma innovation.
Additional Thoughts
In the ever-evolving landscape of biopharma, collaboration and innovation reign supreme. The partnership between Abzena, Revvity, and ProteoNic exemplifies the power of synergy in driving groundbreaking advancements that propel the industry forward. As we look to the future, one thing is certain – the fusion of cutting-edge technologies and unwavering dedication to customer success will continue to shape the biopharma landscape in ways we can only imagine.
Tags: biopharma
Read more on pharmabiz.com